Chevron Is Taking a $3 Billion to $4 Billion Loss on Hess Midstream. Should You Buy the Stock Anyway? NASDAQ · Markets 51m ago
Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer NASDAQ · Markets 59m ago